<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00962585</url>
  </required_header>
  <id_info>
    <org_study_id>AUS-CT03</org_study_id>
    <nct_id>NCT00962585</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of S-equol on Vasomotor Symptoms in Menopausal Patients</brief_title>
  <official_title>Randomized, Double Blind, Multicenter, Placebo Controlled, Proof of Concept Trial to Assess the Efficacy and Safety of 4 Weeks Treatment With AUS-131 (S-equol) on Vasomotor Symptoms in Menopausal Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ausio Pharmaceuticals, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ausio Pharmaceuticals, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and effectiveness of S-equol in menopausal
      patients with hot flushes and night sweats.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a randomized, double blind, multicenter, placebo controlled, parallel group,
      proof of concept study comparing the efficacy, safety, and acceptability of 3 doses of
      S-equol to placebo in menopausal patients with vasomotor symptoms. The study objective is an
      evaluation of the dose response of 3 dose levels of AUS-131 (S-equol) and placebo with
      respect to reducing the mean number of moderate to severe vasomotor symptoms after 4 weeks of
      treatment. The safety of S-equol will be evaluated during the study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change in Frequency of Moderate to Severe Vasomotor Symptoms (MSVS) Baseline at Week 4 (2-week Period)</measure>
    <time_frame>4 weeks from Baseline (2-week run-in period)</time_frame>
    <description>The primary efficacy endpoint for this study was the change from Baseline (Day 0) in the frequency of MSVS (difference between Baseline [2-week run-in period] and Week 4), where the baseline MSVS frequency was captured over 14 ± 2 day period. Moderate is defined as &quot;sensation of heat with sweating, able to continue activity&quot;; severe is defined as &quot;sensation of heat with sweating, causing cessation of activity&quot;. Patients used the take-home daily diary to record MSVS information during the run-in period and treatment period and analyses were performed as specified.
Treatment group differences are estimated using least squares (LS) means and 95% confidence intervals based on the mean square error from the ANCOVA. LSMeans refer to overall adjusted mean frequency of MSVS.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Frequency of MSVS From Baseline at Week 4 (1-week Period)</measure>
    <time_frame>4 weeks from Baseline (period following first 7 days of 2-week run-in period)</time_frame>
    <description>Change from Baseline in the frequency of MSVS (difference between Baseline [period following first 7 days of 2-week run-in period] and period following first 7 days of 2-week Week 4 period), where the Baseline MSVS frequency was captured at visit 3 (Day 0), in the period following the first 7 days, as per CRF. Note: this endpoint is identical to the primary endpoint, however, instead of a 14 ± 2 day period, the period following the first 7 days was used, at Baseline and visit 3.
Treatment group differences are estimated using least squares (LS) means and 95% confidence intervals based on the mean square error from the ANCOVA. LSMeans refer to overall adjusted mean frequency of MSVS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline (Day 0) in the Frequency of MSVS at Week 1 and Week 2</measure>
    <time_frame>1 and 2 weeks from Baseline (Day 0)</time_frame>
    <description>The frequency of MSVS per week, at each of the protocol visits, was calculated as follows, for each patient: [# of Moderate+Severe hot flushes)/(Current protocol visit date-Previous protocol visit date (days)] * 7.
The ANCOVA procedure tested the following hypotheses:
H0: μ1 = μp versus HA: μ1 ≠ μp, where μ1 and μp denote the mean frequency of MSVS, adjusted for Baseline MSVS values, in the treatment and placebo groups, respectively.
LSMeans refer to the overall adjusted mean frequecy of MSVS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline (Day 0) in the Severity of VMS as Recorded in the Patient Diary at Week 1, Week 2, and Week 4</measure>
    <time_frame>1, 2, and 4 weeks from Baseline (Day 0)</time_frame>
    <description>The severity of vasomotor symptoms per week at each of the protocol visits was calculated for each patient as follows: [(Sum of scores of Mild, Moderate, Severe hot flushes)/(Current protocol visit date - Previous protocol visit date (days)] * 7, where severity of vasomotor symptoms were scored as: 1 = mild, 2 = moderate and 3 = severe. Higher values represented worse severity.
LSMeans refer to the overall adjusted mean severity of VMS.
Hot Flush Classification: Mild: sensation of heat without sweating; Moderate: sensation of heat with sweating, able to continue activity; Severe: sensation of heat with sweating, causing cessation of activity.
Patients recorded the number of hot flushes (day and night) in their diaries related to the severity (mild/moderate/severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline (Day 0) in Vaginal pH at Week 2 and Week 4</measure>
    <time_frame>2 and 4 weeks from Baseline (Day 0)</time_frame>
    <description>The pH scale measures how acidic or basic a substance is. The pH scale ranges from 0 to 14. A pH of 7 is neutral. A pH less than 7 is acidic. A pH greater than 7 is basic. The pH scale is logarithmic and as a result, each whole pH value below 7 is ten times more acidic than the next higher value.
Normal vaginal pH is 3.8 to 4.5, slightly acidic.
The LSMeans refer to overall adjusted mean pH.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Vaginal Maturation Index at Week 2 and Week 4</measure>
    <time_frame>2 and 4 weeks from Baseline (Day 0)</time_frame>
    <description>The Vaginal Maturation Index was calculated by examining the maturation of the vaginal epithelium as adjudged by the cell types exfoliated. Parabasal cells are the least mature cells, intermediate cells display mild maturation, and superficial cells display the most maturity. The cell count is expressed as a percentage. The Vaginal Maturation Index was calculated as: 0.2*(parabasal cells, %)+0.6*(intermediate cells, %)+1.0*(superficial cells, %). This method is described in Menopause 2005;12(6):708-15.
The index serves as an objective means of evaluating hormonal secretion or response; lower values indicate more immature cells on the surface (atrophy), while higher values indicate more mature epithelium.
The LSMeans refer to overall adjusted mean percent of cells counted.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Estradiol Concentration at Weeks 2 and 4</measure>
    <time_frame>2 and 4 weeks from Baseline (Day 0)</time_frame>
    <description>The LSMeans refer to overall adjusted mean estradiol concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Progesterone Concentration at Week 2 and Week 4</measure>
    <time_frame>2 and 4 weeks from Baseline (Day 0)</time_frame>
    <description>No repeated measures ANCOVA results are presented for change from Baseline in progesterone concentrations since the model did not converge.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in the Menopause Rating Scale Total Score From Baseline at Week 4</measure>
    <time_frame>4 weeks from Baseline (Day 0)</time_frame>
    <description>MRS consists of 11 menopause symptoms. The scoring scheme is simple, i.e., the score increases point by point with increasing severity of subjectively perceived symptoms in each of the 11 items (severity 0 [no complaints] 4 scoring points [extremely severe symptoms]). The respondent provides her personal perception by checking one of 5 possible boxes of &quot;severity&quot; for each of the items. The composite score (total score) is the sum of the 11 item scores, which can range from 0 (no symptoms) to 44 (extremely severe symptoms). Low total scores represent less severe menopause symptoms while higher scores represent more severe symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Precentage Change in the Menopause Rating Scale Total Score From Baseline at Week 4</measure>
    <time_frame>4 weeks from Baseline (Day 0)</time_frame>
    <description>Percentage change from Baseline at Week 4 = (Week 4 value - Day 0 value)/(Day 0 value) x 100. Note: MRS consists of 11 symptoms, where each symptom is assigned a score from 0 to 4 (0 = 'None' and 4 = 'Extremely severe').</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">169</enrollment>
  <condition>Menopause</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>S-equol 10 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>S-equol 20 mg total daily dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>S-equol 50 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>S-equol 100 mg total daily dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>S-equol 150 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>S-equol 300 mg total daily dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S-equol</intervention_name>
    <description>Eligible patients meeting all study entry criteria were randomly assigned to receive one of the following active treatments for 4 weeks:
S-equol 10 mg BID (20 mg total daily dose)
S-equol 50 mg BID (100 mg total daily dose)
S-equol 150 mg BID (300 mg total daily dose)</description>
    <arm_group_label>S-equol 10 mg BID</arm_group_label>
    <arm_group_label>S-equol 50 mg BID</arm_group_label>
    <arm_group_label>S-equol 150 mg BID</arm_group_label>
    <other_name>AUS-131</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  12 months of spontaneous amenorrhea, or 6 months of spontaneous amenorrhea with serum
             follicle stimulating hormone (FSH) concentrations &gt; 40 mIU/mL, or 6 weeks postsurgical
             bilateral oophorectomy with or without hysterectomy, or hysterectomy with 2 (measured
             14 days apart) serum FSH concentrations &gt; 40 mIU/mL.

          -  Is likely to experience at least 50 moderate to severe vasomotor symptoms ([MSVS] hot
             flushes and nocturnal sweating) per week while not receiving estrogen replacement
             therapy based on history of menopause, in the judgment of the investigator.

          -  Documented experiencing at least 50 MSVS per week during the 14 day baseline period
             before the Randomization Visit (Visit 3), based on the patient diary entries
             (calculated mean MSVS/week for the 14 day baseline period).

          -  If ≥ 40 years of age, has a documented negative mammogram and a normal clinical breast
             examination with no findings indicative of breast malignancy.

          -  Has a body mass index (BMI) &lt; 35.0 kg/m2.

        Exclusion Criteria:

          -  Has a known history of allergic reaction or clinically significant intolerance to
             ingredients of the study drug.

          -  Received any of the following:oral or dermal estrogen/progestin or selective estrogen
             receptor modulator (SERM) containing drug product therapy within 8 weeks before
             Screening, injectable or implantable estrogen/progestin therapy within 3 months before
             Screening, hormone releasing intrauterine device

          -  Had unexplained or otherwise abnormal vaginal bleeding within 6 months before
             Screening.

          -  Has a history of, or currently has, any of the following conditions: thrombophlebitis,
             thromboembolic disease, estrogen dependent neoplasia, or carcinoma of the breast.

          -  Has a history of any untreated or uncontrolled endocrine disorders (e.g.,
             hyperparathyroidism, uncontrolled hyperthyroidism).

          -  Has any clinically significant unstable cardiac, respiratory, neurological,
             immunological, hematological, hepatic, renal, endocrine, or gastric disease or any
             other condition that, in the opinion of the investigator, could compromise the
             patient's welfare, ability to communicate with the study staff, or otherwise
             contraindicate study participation.

          -  Has clinically significant depression or severe psychiatric disturbances.

          -  Has active liver disease with aspartate aminotransferase (AST) &gt; 3 times the upper
             limit of normal (ULN), alanine aminotransferase (ALT) &gt; 3 times ULN, unexplained
             alkaline phosphatase &gt; 3 times ULN, total bilirubin &gt; 2 times ULN, renal insufficiency
             with creatinine &gt; 1.7 mg/dL, or clinically significant abnormal hemoglobin, white
             blood cell count, or platelet count.

          -  Has an endometrial thickness ≥ 4 mm.

          -  Has a history indicative of endometrial hyperplasia or cancer.

          -  Shows presence of any manifest premalignant or malignant disease except treated skin
             cancers (except melanoma).

          -  Has known or suspected history of alcoholism or drug abuse or misuse within the past 5
             years.

          -  Has resting systolic blood pressure (BP) &gt; 160 mmHg or &lt; 90 mmHg, or diastolic BP &gt; 90
             mmHg or &lt; 60 mmHg at Screening.

          -  Has a history of smoking more than 5 cigarettes daily within the year before
             Screening.

          -  Has tested positive on the urine drug screen. Patients who test positive at Screening
             and can produce documentation from their physician for the medication that caused the
             positive test may be considered for study enrollment at the discretion of the
             investigator.

          -  Has significant difficulties swallowing capsules or is unable to tolerate oral
             medication.

          -  Has participated in another clinical trial or received any investigational drug or
             device or investigational therapy within 30 days before Screening.

          -  Has a disorder that affects gastrointestinal absorption.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael A Thomas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cincinnati</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bluegrass Clinical Research</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40291</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Greater Cincinnati OB/GYN, Inc.</name>
      <address>
        <city>Cincinnati,</city>
        <state>Ohio</state>
        <zip>45267-0457</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rapid Medical Research</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research, Inc</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29621</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Clinical Research</name>
      <address>
        <city>West Jordon</city>
        <state>Utah</state>
        <zip>84088</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sydney Centre for Reproductive Health Research</name>
      <address>
        <city>Ashfield</city>
        <state>New South Wales</state>
        <zip>2131</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Hospital for Women</name>
      <address>
        <city>Randwick</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women's Health Center, Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emeritus Research</name>
      <address>
        <city>Malvern East</city>
        <state>Victoria</state>
        <zip>3144</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 19, 2009</study_first_submitted>
  <study_first_submitted_qc>August 19, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 20, 2009</study_first_posted>
  <results_first_submitted>May 7, 2013</results_first_submitted>
  <results_first_submitted_qc>March 11, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 8, 2014</results_first_posted>
  <last_update_submitted>March 11, 2014</last_update_submitted>
  <last_update_submitted_qc>March 11, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 8, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Equol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients for this trial were screened from 9 investigative sites in the United States and Australia. Participants were women of menopausal status and experiencing vasomotor symptoms and nocturnal sweating.</recruitment_details>
      <pre_assignment_details>After completing screening visit assessments, subjects were instructed to refrain from taking prohibited medications throughout the study. Patients who were taking prohibited medications at the time of the screening visit discontinued their use and completed a suitable washout period before progressing to the next visit.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>S-equol 10 mg BID</title>
          <description>20 mg total daily dose of S-equol</description>
        </group>
        <group group_id="P2">
          <title>S-equol 50 mg BID</title>
          <description>100 mg total daily dose of S-equol</description>
        </group>
        <group group_id="P3">
          <title>S-equol 150 mg BID</title>
          <description>300 mg total daily dose of S-equol</description>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
          <description>Placebo treatment arm</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="42"/>
                <participants group_id="P3" count="42"/>
                <participants group_id="P4" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="40"/>
                <participants group_id="P3" count="39"/>
                <participants group_id="P4" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrew Consent</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>S-equol 10 mg BID</title>
          <description>20 mg total daily dose of S-equol</description>
        </group>
        <group group_id="B2">
          <title>S-equol 50 mg BID</title>
          <description>100 mg total daily dose of S-equol</description>
        </group>
        <group group_id="B3">
          <title>S-equol 150 mg BID</title>
          <description>300 mg total daily dose of S-equol</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>Placebo treatment arm</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="43"/>
            <count group_id="B2" value="42"/>
            <count group_id="B3" value="42"/>
            <count group_id="B4" value="42"/>
            <count group_id="B5" value="169"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.8" spread="7.9"/>
                    <measurement group_id="B2" value="53.1" spread="6.9"/>
                    <measurement group_id="B3" value="54.9" spread="5.8"/>
                    <measurement group_id="B4" value="56.2" spread="6.7"/>
                    <measurement group_id="B5" value="54.5" spread="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="42"/>
                    <measurement group_id="B4" value="42"/>
                    <measurement group_id="B5" value="169"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="32"/>
                    <measurement group_id="B4" value="34"/>
                    <measurement group_id="B5" value="140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>centimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="165.3" spread="5.1"/>
                    <measurement group_id="B2" value="164.1" spread="4.6"/>
                    <measurement group_id="B3" value="165.4" spread="6.7"/>
                    <measurement group_id="B4" value="163.3" spread="5.9"/>
                    <measurement group_id="B5" value="164.5" spread="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74.1" spread="11.6"/>
                    <measurement group_id="B2" value="73.0" spread="10.7"/>
                    <measurement group_id="B3" value="74.4" spread="10.1"/>
                    <measurement group_id="B4" value="73.2" spread="12.8"/>
                    <measurement group_id="B5" value="73.7" spread="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kilogram/meter^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.1" spread="3.9"/>
                    <measurement group_id="B2" value="27.1" spread="4.1"/>
                    <measurement group_id="B3" value="27.2" spread="3.5"/>
                    <measurement group_id="B4" value="27.4" spread="4.1"/>
                    <measurement group_id="B5" value="27.2" spread="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Change in Frequency of Moderate to Severe Vasomotor Symptoms (MSVS) Baseline at Week 4 (2-week Period)</title>
        <description>The primary efficacy endpoint for this study was the change from Baseline (Day 0) in the frequency of MSVS (difference between Baseline [2-week run-in period] and Week 4), where the baseline MSVS frequency was captured over 14 ± 2 day period. Moderate is defined as “sensation of heat with sweating, able to continue activity”; severe is defined as “sensation of heat with sweating, causing cessation of activity”. Patients used the take-home daily diary to record MSVS information during the run-in period and treatment period and analyses were performed as specified.
Treatment group differences are estimated using least squares (LS) means and 95% confidence intervals based on the mean square error from the ANCOVA. LSMeans refer to overall adjusted mean frequency of MSVS.</description>
        <time_frame>4 weeks from Baseline (2-week run-in period)</time_frame>
        <population>The analysis population consists of all randomized patients who received at least 1 dose of randomized study drug starting at visit 3, who had at least 1 post-dose efficacy assessment. Missing efficacy data were not imputed.</population>
        <group_list>
          <group group_id="O1">
            <title>S-equol 10 mg BID</title>
            <description>20 mg total daily dose of S-equol</description>
          </group>
          <group group_id="O2">
            <title>S-equol 50 mg BID</title>
            <description>100 mg total daily dose of S-equol</description>
          </group>
          <group group_id="O3">
            <title>S-equol 150 mg BID</title>
            <description>300 mg total daily dose of S-equol</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo treatment arm</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Frequency of Moderate to Severe Vasomotor Symptoms (MSVS) Baseline at Week 4 (2-week Period)</title>
          <description>The primary efficacy endpoint for this study was the change from Baseline (Day 0) in the frequency of MSVS (difference between Baseline [2-week run-in period] and Week 4), where the baseline MSVS frequency was captured over 14 ± 2 day period. Moderate is defined as “sensation of heat with sweating, able to continue activity”; severe is defined as “sensation of heat with sweating, causing cessation of activity”. Patients used the take-home daily diary to record MSVS information during the run-in period and treatment period and analyses were performed as specified.
Treatment group differences are estimated using least squares (LS) means and 95% confidence intervals based on the mean square error from the ANCOVA. LSMeans refer to overall adjusted mean frequency of MSVS.</description>
          <population>The analysis population consists of all randomized patients who received at least 1 dose of randomized study drug starting at visit 3, who had at least 1 post-dose efficacy assessment. Missing efficacy data were not imputed.</population>
          <units>Number of MSVS/2 weeks</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="41"/>
                <count group_id="O4" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Day 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.5" lower_limit="65.3" upper_limit="81.8"/>
                    <measurement group_id="O2" value="69.5" lower_limit="64.0" upper_limit="75.1"/>
                    <measurement group_id="O3" value="70.4" lower_limit="63.5" upper_limit="77.3"/>
                    <measurement group_id="O4" value="67.9" lower_limit="61.4" upper_limit="74.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.7" spread="32.8" lower_limit="31.0" upper_limit="52.5"/>
                    <measurement group_id="O2" value="46.1" spread="27.8" lower_limit="37.5" upper_limit="54.8"/>
                    <measurement group_id="O3" value="39.3" spread="27.3" lower_limit="30.5" upper_limit="48.0"/>
                    <measurement group_id="O4" value="39.3" spread="25.1" lower_limit="31.5" upper_limit="47.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-30.1" spread="29.0" lower_limit="-39.7" upper_limit="-20.6"/>
                    <measurement group_id="O2" value="-23.4" spread="30.2" lower_limit="-32.8" upper_limit="-14.0"/>
                    <measurement group_id="O3" value="-31.1" spread="23.4" lower_limit="-38.6" upper_limit="-23.7"/>
                    <measurement group_id="O4" value="-28.6" spread="22.1" lower_limit="-35.5" upper_limit="-21.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LSMean</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.78" lower_limit="32.72" upper_limit="48.84"/>
                    <measurement group_id="O2" value="46.63" lower_limit="38.87" upper_limit="54.39"/>
                    <measurement group_id="O3" value="40.59" lower_limit="32.58" upper_limit="48.59"/>
                    <measurement group_id="O4" value="39.65" lower_limit="31.89" upper_limit="47.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc># of MSVS per week at each protocol visits = (# of Moderate+Severe hot flushes)/(Current protocol visit date-Previous protocol visit date (days)) x 7.
The ANCOVA procedure was used to test the following hypotheses:
H0: μ1 = μp versus HA: μ1 ≠ μp where μ1 and μp denote the mean frequency of MSVS (at Week 4 in case of primary efficacy endpoint), adjusted for Baseline MSVS values, in the treatment and placebo groups, respectively.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5730</p_value>
            <p_value_desc>P-value was not adjusted for multiple comparisons and the a priori threshold for statistical significance was P &lt;0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model (Analysis of covariance): Week 4 = Baseline (MSVS) + Treatment + Site
Difference Between Means: S-equol treatment group - Placebo</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Pair-wise comparisons</method>
            <param_type>LS means difference</param_type>
            <param_value>1.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.06</ci_lower_limit>
            <ci_upper_limit>12.32</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Pair-wise comparisons</method>
            <param_type>LS means difference</param_type>
            <param_value>6.98</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.87</ci_lower_limit>
            <ci_upper_limit>17.84</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Pair-wise comparisons</method>
            <param_type>LS means difference</param_type>
            <param_value>0.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.16</ci_lower_limit>
            <ci_upper_limit>12.04</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Frequency of MSVS From Baseline at Week 4 (1-week Period)</title>
        <description>Change from Baseline in the frequency of MSVS (difference between Baseline [period following first 7 days of 2-week run-in period] and period following first 7 days of 2-week Week 4 period), where the Baseline MSVS frequency was captured at visit 3 (Day 0), in the period following the first 7 days, as per CRF. Note: this endpoint is identical to the primary endpoint, however, instead of a 14 ± 2 day period, the period following the first 7 days was used, at Baseline and visit 3.
Treatment group differences are estimated using least squares (LS) means and 95% confidence intervals based on the mean square error from the ANCOVA. LSMeans refer to overall adjusted mean frequency of MSVS.</description>
        <time_frame>4 weeks from Baseline (period following first 7 days of 2-week run-in period)</time_frame>
        <population>The analysis population consists of all randomized patients who received at least 1 dose of randomized study drug starting at visit 3, who had at least 1 post-dose efficacy assessment. Missing efficacy data were not imputed.</population>
        <group_list>
          <group group_id="O1">
            <title>S-equol 10 mg BID</title>
            <description>20 mg total daily dose of S-equol</description>
          </group>
          <group group_id="O2">
            <title>S-equol 50 mg BID</title>
            <description>100 mg total daily dose of S-equol</description>
          </group>
          <group group_id="O3">
            <title>S-equol 150 mg BID</title>
            <description>300 mg total daily dose of S-equol</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo treatment arm</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Frequency of MSVS From Baseline at Week 4 (1-week Period)</title>
          <description>Change from Baseline in the frequency of MSVS (difference between Baseline [period following first 7 days of 2-week run-in period] and period following first 7 days of 2-week Week 4 period), where the Baseline MSVS frequency was captured at visit 3 (Day 0), in the period following the first 7 days, as per CRF. Note: this endpoint is identical to the primary endpoint, however, instead of a 14 ± 2 day period, the period following the first 7 days was used, at Baseline and visit 3.
Treatment group differences are estimated using least squares (LS) means and 95% confidence intervals based on the mean square error from the ANCOVA. LSMeans refer to overall adjusted mean frequency of MSVS.</description>
          <population>The analysis population consists of all randomized patients who received at least 1 dose of randomized study drug starting at visit 3, who had at least 1 post-dose efficacy assessment. Missing efficacy data were not imputed.</population>
          <units>Number of MSVS/week</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="41"/>
                <count group_id="O4" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Day 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.0" lower_limit="64.3" upper_limit="81.7"/>
                    <measurement group_id="O2" value="71.4" lower_limit="65.4" upper_limit="77.4"/>
                    <measurement group_id="O3" value="69.5" lower_limit="62.0" upper_limit="76.9"/>
                    <measurement group_id="O4" value="67.9" lower_limit="60.1" upper_limit="75.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.0" lower_limit="27.5" upper_limit="52.5"/>
                    <measurement group_id="O2" value="45.5" lower_limit="36.3" upper_limit="54.6"/>
                    <measurement group_id="O3" value="37.1" lower_limit="28.2" upper_limit="46.1"/>
                    <measurement group_id="O4" value="40.2" lower_limit="31.5" upper_limit="48.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-30.2" lower_limit="-40.9" upper_limit="-19.6"/>
                    <measurement group_id="O2" value="-24.9" lower_limit="-35.0" upper_limit="-14.8"/>
                    <measurement group_id="O3" value="-32.6" lower_limit="-41.1" upper_limit="-24.0"/>
                    <measurement group_id="O4" value="-27.6" lower_limit="-35.3" upper_limit="-20.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LSMean</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.04" lower_limit="31.02" upper_limit="49.06"/>
                    <measurement group_id="O2" value="44.99" lower_limit="36.50" upper_limit="53.49"/>
                    <measurement group_id="O3" value="38.60" lower_limit="30.09" upper_limit="47.10"/>
                    <measurement group_id="O4" value="40.23" lower_limit="32.00" upper_limit="48.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc># of MSVS per week at each protocol visits = (# of Moderate+Severe hot flushes)/(Current protocol visit date–Previous protocol visit date (days)) x 7
1-week period = remaining days of the period since the last visit (i.e. period following first 7 days, as per CRF)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7364</p_value>
            <p_value_desc>P-value was not adjusted for multiple comparisons and the a priori threshold for statistical significance was P &lt;0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model: Week 4 = Baseline (MSVS) + Treatment + Site
Difference Between Means: S-equol treatment group - Placebo</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Pair-wise comparisons</method>
            <param_type>LS means difference</param_type>
            <param_value>-0.19</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.38</ci_lower_limit>
            <ci_upper_limit>12.01</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Pair-wise comparisons</method>
            <param_type>LS means difference</param_type>
            <param_value>4.77</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.94</ci_lower_limit>
            <ci_upper_limit>16.48</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Pair-wise comparisons</method>
            <param_type>LS means difference</param_type>
            <param_value>-1.63</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.41</ci_lower_limit>
            <ci_upper_limit>10.15</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline (Day 0) in the Frequency of MSVS at Week 1 and Week 2</title>
        <description>The frequency of MSVS per week, at each of the protocol visits, was calculated as follows, for each patient: [# of Moderate+Severe hot flushes)/(Current protocol visit date–Previous protocol visit date (days)] * 7.
The ANCOVA procedure tested the following hypotheses:
H0: μ1 = μp versus HA: μ1 ≠ μp, where μ1 and μp denote the mean frequency of MSVS, adjusted for Baseline MSVS values, in the treatment and placebo groups, respectively.
LSMeans refer to the overall adjusted mean frequecy of MSVS.</description>
        <time_frame>1 and 2 weeks from Baseline (Day 0)</time_frame>
        <population>The analysis population consists of all randomized patients who received at least 1 dose of randomized study drug starting at visit 3, who had at least 1 post-dose efficacy assessment. Missing efficacy data were not imputed.</population>
        <group_list>
          <group group_id="O1">
            <title>S-equol 10 mg BID</title>
            <description>20 mg total daily dose of S-equol</description>
          </group>
          <group group_id="O2">
            <title>S-equol 50 mg BID</title>
            <description>100 mg total daily dose of S-equol</description>
          </group>
          <group group_id="O3">
            <title>S-equol 150 mg BID</title>
            <description>300 mg total daily dose of S-equol</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo treatment arm</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline (Day 0) in the Frequency of MSVS at Week 1 and Week 2</title>
          <description>The frequency of MSVS per week, at each of the protocol visits, was calculated as follows, for each patient: [# of Moderate+Severe hot flushes)/(Current protocol visit date–Previous protocol visit date (days)] * 7.
The ANCOVA procedure tested the following hypotheses:
H0: μ1 = μp versus HA: μ1 ≠ μp, where μ1 and μp denote the mean frequency of MSVS, adjusted for Baseline MSVS values, in the treatment and placebo groups, respectively.
LSMeans refer to the overall adjusted mean frequecy of MSVS.</description>
          <population>The analysis population consists of all randomized patients who received at least 1 dose of randomized study drug starting at visit 3, who had at least 1 post-dose efficacy assessment. Missing efficacy data were not imputed.</population>
          <units>Number of MSVS/week</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="41"/>
                <count group_id="O4" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.6" lower_limit="47.4" upper_limit="59.8"/>
                    <measurement group_id="O2" value="63.1" lower_limit="55.5" upper_limit="70.8"/>
                    <measurement group_id="O3" value="54.4" lower_limit="45.0" upper_limit="63.7"/>
                    <measurement group_id="O4" value="54.1" lower_limit="46.6" upper_limit="61.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.9" lower_limit="-28.6" upper_limit="-11.2"/>
                    <measurement group_id="O2" value="-6.7" lower_limit="-12.7" upper_limit="-0.7"/>
                    <measurement group_id="O3" value="-15.9" lower_limit="-21.6" upper_limit="-10.2"/>
                    <measurement group_id="O4" value="-13.8" lower_limit="-18.8" upper_limit="-8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1, LSMean</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.95" lower_limit="44.67" upper_limit="57.24"/>
                    <measurement group_id="O2" value="64.41" lower_limit="58.04" upper_limit="70.78"/>
                    <measurement group_id="O3" value="56.03" lower_limit="49.52" upper_limit="62.55"/>
                    <measurement group_id="O4" value="54.72" lower_limit="48.38" upper_limit="61.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.3" lower_limit="38.5" upper_limit="56.2"/>
                    <measurement group_id="O2" value="54.3" lower_limit="44.2" upper_limit="64.4"/>
                    <measurement group_id="O3" value="51.0" lower_limit="40.7" upper_limit="61.2"/>
                    <measurement group_id="O4" value="50.0" lower_limit="41.4" upper_limit="58.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.3" lower_limit="-31.2" upper_limit="-15.3"/>
                    <measurement group_id="O2" value="-14.8" lower_limit="-25.0" upper_limit="-4.6"/>
                    <measurement group_id="O3" value="-19.4" lower_limit="-26.6" upper_limit="-12.2"/>
                    <measurement group_id="O4" value="-17.9" lower_limit="-25.5" upper_limit="-10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2, LSMean</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.96" lower_limit="35.67" upper_limit="52.24"/>
                    <measurement group_id="O2" value="54.22" lower_limit="45.97" upper_limit="62.47"/>
                    <measurement group_id="O3" value="51.56" lower_limit="43.21" upper_limit="59.92"/>
                    <measurement group_id="O4" value="50.66" lower_limit="42.45" upper_limit="58.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc># of MSVS per week at each protocol visits = (# of Moderate+Severe hot flushes)/(Current protocol visit date-Previous protocol visit date (days)) x 7.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1217</p_value>
            <p_value_desc>P-value was not adjusted for multiple comparisons and the a priori threshold for statistical significance was P &lt;0.05. Treatment effect averaged across Weeks 1 and 2.</p_value_desc>
            <method>Repeated measures ANCOVA</method>
            <method_desc>Mixed Model: MSVS = Baseline (MSVS) + Treatment + Site + Weeks + Treatment x Weeks
Difference Between Means: S-equol treatment group - Placebo</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 1, Treatment Effect</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Pair-wise comparisons</method>
            <param_type>LS means difference</param_type>
            <param_value>-3.77</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-12.69</ci_lower_limit>
            <ci_upper_limit>5.16</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 1, Treatment Effect</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Pair-wise comparisons</method>
            <param_type>LS means difference</param_type>
            <param_value>9.69</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.79</ci_lower_limit>
            <ci_upper_limit>18.60</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 1, Treatment Effect</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Pair-wise comparisons</method>
            <param_type>LS means difference</param_type>
            <param_value>1.31</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.73</ci_lower_limit>
            <ci_upper_limit>10.36</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 2, Treatment Effect</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Pair-wise comparisons</method>
            <param_type>LS means difference</param_type>
            <param_value>-6.70</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-18.36</ci_lower_limit>
            <ci_upper_limit>4.96</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 2, Treatment Effect</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Pair-wise comparisons</method>
            <param_type>LS means difference</param_type>
            <param_value>3.56</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.01</ci_lower_limit>
            <ci_upper_limit>15.14</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 2, Treatment Effect</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Pair-wise comparisons</method>
            <param_type>LS means difference</param_type>
            <param_value>0.91</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.77</ci_lower_limit>
            <ci_upper_limit>12.58</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline (Day 0) in the Severity of VMS as Recorded in the Patient Diary at Week 1, Week 2, and Week 4</title>
        <description>The severity of vasomotor symptoms per week at each of the protocol visits was calculated for each patient as follows: [(Sum of scores of Mild, Moderate, Severe hot flushes)/(Current protocol visit date – Previous protocol visit date (days)] * 7, where severity of vasomotor symptoms were scored as: 1 = mild, 2 = moderate and 3 = severe. Higher values represented worse severity.
LSMeans refer to the overall adjusted mean severity of VMS.
Hot Flush Classification: Mild: sensation of heat without sweating; Moderate: sensation of heat with sweating, able to continue activity; Severe: sensation of heat with sweating, causing cessation of activity.
Patients recorded the number of hot flushes (day and night) in their diaries related to the severity (mild/moderate/severe).</description>
        <time_frame>1, 2, and 4 weeks from Baseline (Day 0)</time_frame>
        <population>The analysis population consists of all randomized patients who received at least 1 dose of randomized study drug starting at visit 3, who had at least 1 post-dose efficacy assessment. Missing efficacy data were not imputed.</population>
        <group_list>
          <group group_id="O1">
            <title>S-equol 10 mg BID</title>
            <description>20 mg total daily dose of S-equol</description>
          </group>
          <group group_id="O2">
            <title>S-equol 50 mg BID</title>
            <description>100 mg total daily dose of S-equol</description>
          </group>
          <group group_id="O3">
            <title>S-equol 150 mg BID</title>
            <description>300 mg total daily dose of S-equol</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo treatment arm</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline (Day 0) in the Severity of VMS as Recorded in the Patient Diary at Week 1, Week 2, and Week 4</title>
          <description>The severity of vasomotor symptoms per week at each of the protocol visits was calculated for each patient as follows: [(Sum of scores of Mild, Moderate, Severe hot flushes)/(Current protocol visit date – Previous protocol visit date (days)] * 7, where severity of vasomotor symptoms were scored as: 1 = mild, 2 = moderate and 3 = severe. Higher values represented worse severity.
LSMeans refer to the overall adjusted mean severity of VMS.
Hot Flush Classification: Mild: sensation of heat without sweating; Moderate: sensation of heat with sweating, able to continue activity; Severe: sensation of heat with sweating, causing cessation of activity.
Patients recorded the number of hot flushes (day and night) in their diaries related to the severity (mild/moderate/severe).</description>
          <population>The analysis population consists of all randomized patients who received at least 1 dose of randomized study drug starting at visit 3, who had at least 1 post-dose efficacy assessment. Missing efficacy data were not imputed.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="41"/>
                <count group_id="O4" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Day 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="188.6" lower_limit="168.1" upper_limit="209.1"/>
                    <measurement group_id="O2" value="177.1" lower_limit="161.0" upper_limit="193.2"/>
                    <measurement group_id="O3" value="175.6" lower_limit="158.8" upper_limit="192.4"/>
                    <measurement group_id="O4" value="172.8" lower_limit="155.9" upper_limit="189.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="139.0" lower_limit="123.1" upper_limit="155.0"/>
                    <measurement group_id="O2" value="160.4" lower_limit="139.5" upper_limit="181.3"/>
                    <measurement group_id="O3" value="133.6" lower_limit="113.9" upper_limit="153.4"/>
                    <measurement group_id="O4" value="136.0" lower_limit="116.8" upper_limit="155.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-49.5" lower_limit="-66.7" upper_limit="-32.4"/>
                    <measurement group_id="O2" value="-17.5" lower_limit="-32.6" upper_limit="-2.5"/>
                    <measurement group_id="O3" value="-41.8" lower_limit="-55.8" upper_limit="-27.8"/>
                    <measurement group_id="O4" value="-36.8" lower_limit="-48.3" upper_limit="-25.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1, LSMean</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="130.93" lower_limit="116.79" upper_limit="145.07"/>
                    <measurement group_id="O2" value="162.94" lower_limit="148.61" upper_limit="177.26"/>
                    <measurement group_id="O3" value="139.36" lower_limit="124.72" upper_limit="153.99"/>
                    <measurement group_id="O4" value="137.27" lower_limit="123.02" upper_limit="151.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="122.0" lower_limit="99.5" upper_limit="144.5"/>
                    <measurement group_id="O2" value="140.1" lower_limit="114.3" upper_limit="165.9"/>
                    <measurement group_id="O3" value="126.2" lower_limit="102.7" upper_limit="149.6"/>
                    <measurement group_id="O4" value="128.7" lower_limit="106.3" upper_limit="151.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-60.4" lower_limit="-79.2" upper_limit="-41.7"/>
                    <measurement group_id="O2" value="-35.3" lower_limit="-60.4" upper_limit="-10.2"/>
                    <measurement group_id="O3" value="-49.4" lower_limit="-67.3" upper_limit="-31.6"/>
                    <measurement group_id="O4" value="-44.1" lower_limit="-62.1" upper_limit="-26.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2, LSMean</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113.86" lower_limit="94.57" upper_limit="133.14"/>
                    <measurement group_id="O2" value="138.73" lower_limit="119.57" upper_limit="157.89"/>
                    <measurement group_id="O3" value="129.34" lower_limit="109.92" upper_limit="148.77"/>
                    <measurement group_id="O4" value="130.00" lower_limit="110.89" upper_limit="149.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110.5" lower_limit="83.4" upper_limit="137.7"/>
                    <measurement group_id="O2" value="120.3" lower_limit="98.0" upper_limit="142.6"/>
                    <measurement group_id="O3" value="99.5" lower_limit="78.8" upper_limit="120.3"/>
                    <measurement group_id="O4" value="101.6" lower_limit="83.1" upper_limit="120.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-75.5" lower_limit="-98.0" upper_limit="-53.0"/>
                    <measurement group_id="O2" value="-56.8" lower_limit="-80.8" upper_limit="-32.7"/>
                    <measurement group_id="O3" value="-76.2" lower_limit="-94.9" upper_limit="-57.5"/>
                    <measurement group_id="O4" value="-71.2" lower_limit="-87.8" upper_limit="-54.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4, LSMean</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101.27" lower_limit="81.98" upper_limit="120.56"/>
                    <measurement group_id="O2" value="119.11" lower_limit="100.23" upper_limit="137.99"/>
                    <measurement group_id="O3" value="101.67" lower_limit="82.39" upper_limit="120.94"/>
                    <measurement group_id="O4" value="102.96" lower_limit="84.08" upper_limit="121.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Severity of VMS per week at each protocol visits = (Sum of scores of Mild, Moderate, Severe hot flushes)/(Current protocol visit date–Previous protocol visit date (days)) x 7, where severity of vasomotor symptoms are scored as: 1 = mild, 2 = moderate and 3 = severe.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1609</p_value>
            <p_value_desc>P-value was not adjusted for multiple comparisons and the a priori threshold for statistical significance was P &lt;0.05. Treatment effect averaged across Weeks 1, 2 and 4.</p_value_desc>
            <method>Repeated measures ANCOVA</method>
            <method_desc>Mixed Model: Severity of VMS = Baseline (severity of VMS) + Treatment + Site + Weeks + Treatment x Weeks</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 1, Treatment Effect</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Pair-wise comparisons</method>
            <param_type>LS means difference</param_type>
            <param_value>-6.34</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-26.41</ci_lower_limit>
            <ci_upper_limit>13.73</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 1, Treatment Effect</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Pair-wise comparisons</method>
            <param_type>LS means difference</param_type>
            <param_value>25.67</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.64</ci_lower_limit>
            <ci_upper_limit>45.69</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 1, Treatment Effect</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Pair-wise comparisons</method>
            <param_type>LS means difference</param_type>
            <param_value>2.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-18.21</ci_lower_limit>
            <ci_upper_limit>22.39</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Week 2, Treatment Effect</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Pair-wise comparisons</method>
            <param_type>LS means difference</param_type>
            <param_value>-16.14</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-43.29</ci_lower_limit>
            <ci_upper_limit>11.01</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 2, Treatment Effect</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Pair-wise comparisons</method>
            <param_type>LS means difference</param_type>
            <param_value>8.73</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-18.19</ci_lower_limit>
            <ci_upper_limit>35.65</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 2, Treatment Effect</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Pair-wise comparisons</method>
            <param_type>LS means difference</param_type>
            <param_value>-0.65</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-27.80</ci_lower_limit>
            <ci_upper_limit>26.50</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 4, Treatment Effect</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Pair-wise comparisons</method>
            <param_type>LS means difference</param_type>
            <param_value>-1.69</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-28.68</ci_lower_limit>
            <ci_upper_limit>25.30</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 4, Treatment Effect</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Pair-wise comparisons</method>
            <param_type>LS means difference</param_type>
            <param_value>16.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.40</ci_lower_limit>
            <ci_upper_limit>42.71</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 4, Treatment Effect</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Pair-wise comparisons</method>
            <param_type>LS means difference</param_type>
            <param_value>-1.29</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-28.18</ci_lower_limit>
            <ci_upper_limit>25.60</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline (Day 0) in Vaginal pH at Week 2 and Week 4</title>
        <description>The pH scale measures how acidic or basic a substance is. The pH scale ranges from 0 to 14. A pH of 7 is neutral. A pH less than 7 is acidic. A pH greater than 7 is basic. The pH scale is logarithmic and as a result, each whole pH value below 7 is ten times more acidic than the next higher value.
Normal vaginal pH is 3.8 to 4.5, slightly acidic.
The LSMeans refer to overall adjusted mean pH.</description>
        <time_frame>2 and 4 weeks from Baseline (Day 0)</time_frame>
        <population>The analysis population consists of all randomized patients who received at least 1 dose of randomized study drug starting at visit 3, who had at least 1 post-dose efficacy assessment. Missing efficacy data were not imputed.</population>
        <group_list>
          <group group_id="O1">
            <title>S-equol 10 mg BID</title>
            <description>20 mg total daily dose of S-equol</description>
          </group>
          <group group_id="O2">
            <title>S-equol 50 mg BID</title>
            <description>100 mg total daily dose of S-equol</description>
          </group>
          <group group_id="O3">
            <title>S-equol 150 mg BID</title>
            <description>300 mg total daily dose of S-equol</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo treatment arm</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline (Day 0) in Vaginal pH at Week 2 and Week 4</title>
          <description>The pH scale measures how acidic or basic a substance is. The pH scale ranges from 0 to 14. A pH of 7 is neutral. A pH less than 7 is acidic. A pH greater than 7 is basic. The pH scale is logarithmic and as a result, each whole pH value below 7 is ten times more acidic than the next higher value.
Normal vaginal pH is 3.8 to 4.5, slightly acidic.
The LSMeans refer to overall adjusted mean pH.</description>
          <population>The analysis population consists of all randomized patients who received at least 1 dose of randomized study drug starting at visit 3, who had at least 1 post-dose efficacy assessment. Missing efficacy data were not imputed.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="41"/>
                <count group_id="O4" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Day 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5" lower_limit="5.3" upper_limit="5.8"/>
                    <measurement group_id="O2" value="5.5" lower_limit="5.3" upper_limit="5.8"/>
                    <measurement group_id="O3" value="5.8" lower_limit="5.7" upper_limit="6.0"/>
                    <measurement group_id="O4" value="5.7" lower_limit="5.5" upper_limit="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4" lower_limit="5.2" upper_limit="5.6"/>
                    <measurement group_id="O2" value="5.4" lower_limit="5.2" upper_limit="5.6"/>
                    <measurement group_id="O3" value="5.8" lower_limit="5.5" upper_limit="6.1"/>
                    <measurement group_id="O4" value="5.8" lower_limit="5.5" upper_limit="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" lower_limit="-0.3" upper_limit="0.1"/>
                    <measurement group_id="O2" value="-0.1" lower_limit="-0.3" upper_limit="0.1"/>
                    <measurement group_id="O3" value="-0.0" lower_limit="-0.3" upper_limit="0.3"/>
                    <measurement group_id="O4" value="0.0" lower_limit="-0.2" upper_limit="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2, LSMean</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.51" lower_limit="5.28" upper_limit="5.75"/>
                    <measurement group_id="O2" value="5.49" lower_limit="5.27" upper_limit="5.72"/>
                    <measurement group_id="O3" value="5.75" lower_limit="5.53" upper_limit="5.98"/>
                    <measurement group_id="O4" value="5.72" lower_limit="5.49" upper_limit="5.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4" lower_limit="5.1" upper_limit="5.7"/>
                    <measurement group_id="O2" value="5.5" lower_limit="5.3" upper_limit="5.8"/>
                    <measurement group_id="O3" value="5.6" lower_limit="5.4" upper_limit="5.8"/>
                    <measurement group_id="O4" value="5.8" lower_limit="5.5" upper_limit="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" lower_limit="-0.4" upper_limit="0.1"/>
                    <measurement group_id="O2" value="-0.0" lower_limit="-0.2" upper_limit="0.2"/>
                    <measurement group_id="O3" value="-0.3" lower_limit="-0.5" upper_limit="-0.1"/>
                    <measurement group_id="O4" value="0.0" lower_limit="-0.2" upper_limit="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4, LSMean</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.48" lower_limit="5.28" upper_limit="5.68"/>
                    <measurement group_id="O2" value="5.61" lower_limit="5.42" upper_limit="5.80"/>
                    <measurement group_id="O3" value="5.50" lower_limit="5.30" upper_limit="5.69"/>
                    <measurement group_id="O4" value="5.74" lower_limit="5.55" upper_limit="5.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2211</p_value>
            <p_value_desc>P-value was not adjusted for multiple comparisons and the a priori threshold for statistical significance was P &lt;0.05. Treatment effect averaged across Weeks 2 and 4.</p_value_desc>
            <method>Repeated measures ANCOVA</method>
            <method_desc>Mixed Model: (Vaginal pH) = Baseline (Vaginal pH) + Treatment + Site + Weeks + Treatment x Weeks</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 2, Treatment Effect</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Pair-wise comparisons</method>
            <param_type>LS means difference</param_type>
            <param_value>-0.21</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.53</ci_lower_limit>
            <ci_upper_limit>0.12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 2, Treatment Effect</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Pair-wise comparisons</method>
            <param_type>LS means difference</param_type>
            <param_value>-0.23</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.55</ci_lower_limit>
            <ci_upper_limit>0.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 2, Treatment Effect</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Pair-wise comparisons</method>
            <param_type>LS means difference</param_type>
            <param_value>0.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.28</ci_lower_limit>
            <ci_upper_limit>0.35</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 4, Treatment Effect</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Pair-wise comparisons</method>
            <param_type>LS means difference</param_type>
            <param_value>-0.26</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.54</ci_lower_limit>
            <ci_upper_limit>0.02</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 4, Treatment Effect</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Pair-wise comparisons</method>
            <param_type>LS means difference</param_type>
            <param_value>-0.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.40</ci_lower_limit>
            <ci_upper_limit>0.14</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 4, Treatment Effect</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Pair-wise comparisons</method>
            <param_type>LS means difference</param_type>
            <param_value>-0.24</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.51</ci_lower_limit>
            <ci_upper_limit>0.03</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Vaginal Maturation Index at Week 2 and Week 4</title>
        <description>The Vaginal Maturation Index was calculated by examining the maturation of the vaginal epithelium as adjudged by the cell types exfoliated. Parabasal cells are the least mature cells, intermediate cells display mild maturation, and superficial cells display the most maturity. The cell count is expressed as a percentage. The Vaginal Maturation Index was calculated as: 0.2*(parabasal cells, %)+0.6*(intermediate cells, %)+1.0*(superficial cells, %). This method is described in Menopause 2005;12(6):708-15.
The index serves as an objective means of evaluating hormonal secretion or response; lower values indicate more immature cells on the surface (atrophy), while higher values indicate more mature epithelium.
The LSMeans refer to overall adjusted mean percent of cells counted.</description>
        <time_frame>2 and 4 weeks from Baseline (Day 0)</time_frame>
        <population>The analysis population consists of all randomized patients who received at least 1 dose of randomized study drug starting at visit 3, who had at least 1 post-dose efficacy assessment. Missing efficacy data were not imputed.</population>
        <group_list>
          <group group_id="O1">
            <title>S-equol 10 mg BID</title>
            <description>20 mg total daily dose of S-equol</description>
          </group>
          <group group_id="O2">
            <title>S-equol 50 mg BID</title>
            <description>100 mg total daily dose of S-equol</description>
          </group>
          <group group_id="O3">
            <title>S-equol 150 mg BID</title>
            <description>300 mg total daily dose of S-equol</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo treatment arm</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Vaginal Maturation Index at Week 2 and Week 4</title>
          <description>The Vaginal Maturation Index was calculated by examining the maturation of the vaginal epithelium as adjudged by the cell types exfoliated. Parabasal cells are the least mature cells, intermediate cells display mild maturation, and superficial cells display the most maturity. The cell count is expressed as a percentage. The Vaginal Maturation Index was calculated as: 0.2*(parabasal cells, %)+0.6*(intermediate cells, %)+1.0*(superficial cells, %). This method is described in Menopause 2005;12(6):708-15.
The index serves as an objective means of evaluating hormonal secretion or response; lower values indicate more immature cells on the surface (atrophy), while higher values indicate more mature epithelium.
The LSMeans refer to overall adjusted mean percent of cells counted.</description>
          <population>The analysis population consists of all randomized patients who received at least 1 dose of randomized study drug starting at visit 3, who had at least 1 post-dose efficacy assessment. Missing efficacy data were not imputed.</population>
          <units>percentage of cells</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="41"/>
                <count group_id="O4" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Day 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.6" lower_limit="47.4" upper_limit="57.9"/>
                    <measurement group_id="O2" value="55.7" lower_limit="50.7" upper_limit="60.7"/>
                    <measurement group_id="O3" value="50.9" lower_limit="44.7" upper_limit="57.2"/>
                    <measurement group_id="O4" value="43.5" lower_limit="37.4" upper_limit="49.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.5" lower_limit="49.0" upper_limit="60.1"/>
                    <measurement group_id="O2" value="54.3" lower_limit="47.4" upper_limit="61.1"/>
                    <measurement group_id="O3" value="50.8" lower_limit="43.1" upper_limit="58.6"/>
                    <measurement group_id="O4" value="47.0" lower_limit="41.0" upper_limit="52.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" lower_limit="-3.8" upper_limit="2.4"/>
                    <measurement group_id="O2" value="-1.3" lower_limit="-8.4" upper_limit="5.9"/>
                    <measurement group_id="O3" value="0.6" lower_limit="-6.5" upper_limit="7.7"/>
                    <measurement group_id="O4" value="3.9" lower_limit="-3.0" upper_limit="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2, LSMean</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.89" lower_limit="45.29" upper_limit="56.50"/>
                    <measurement group_id="O2" value="50.89" lower_limit="45.20" upper_limit="56.58"/>
                    <measurement group_id="O3" value="50.88" lower_limit="45.09" upper_limit="56.67"/>
                    <measurement group_id="O4" value="52.47" lower_limit="46.80" upper_limit="58.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.5" lower_limit="50.8" upper_limit="62.2"/>
                    <measurement group_id="O2" value="51.7" lower_limit="45.5" upper_limit="57.9"/>
                    <measurement group_id="O3" value="51.3" lower_limit="45.2" upper_limit="57.5"/>
                    <measurement group_id="O4" value="48.1" lower_limit="42.2" upper_limit="54.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" lower_limit="-2.1" upper_limit="5.5"/>
                    <measurement group_id="O2" value="-3.7" lower_limit="-7.0" upper_limit="-0.3"/>
                    <measurement group_id="O3" value="0.3" lower_limit="-4.6" upper_limit="5.2"/>
                    <measurement group_id="O4" value="5.2" lower_limit="-0.8" upper_limit="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4, LSMean</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.58" lower_limit="48.92" upper_limit="58.24"/>
                    <measurement group_id="O2" value="47.75" lower_limit="43.35" upper_limit="52.14"/>
                    <measurement group_id="O3" value="51.01" lower_limit="46.62" upper_limit="55.40"/>
                    <measurement group_id="O4" value="53.26" lower_limit="49.52" upper_limit="58.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Vaginal maturation index = 0.2 x (% parabasal cells) + 0.6 x(% intermediate cells) + 1.0 x (% superficial cells)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6375</p_value>
            <p_value_desc>P-value was not adjusted for multiple comparisons and the a priori threshold for statistical significance was P &lt;0.05. Treatment effect averaged across Weeks 2 and 4.</p_value_desc>
            <method>Repeated measures ANCOVA</method>
            <method_desc>Mixed Model: (Vaginal Maturation Index) = Baseline (Vaginal Maturation Index) + Treatment + Site + Weeks + Treatment x Weeks</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 2, Treatment Effect</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Pair-wise comparisons</method>
            <param_type>LS means difference</param_type>
            <param_value>-1.58</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.57</ci_lower_limit>
            <ci_upper_limit>6.42</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 2, Treatment Effect</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Pair-wise comparisons</method>
            <param_type>LS means difference</param_type>
            <param_value>-1.58</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.63</ci_lower_limit>
            <ci_upper_limit>6.46</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 2, Treatment Effect</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Pair-wise comparisons</method>
            <param_type>LS means difference</param_type>
            <param_value>-1.59</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.66</ci_lower_limit>
            <ci_upper_limit>6.47</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 4, Treatment Effect</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Pair-wise comparisons</method>
            <param_type>LS means difference</param_type>
            <param_value>-0.31</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.73</ci_lower_limit>
            <ci_upper_limit>6.11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 4, Treatment Effect</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Pair-wise comparisons</method>
            <param_type>LS means difference</param_type>
            <param_value>-6.14</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.36</ci_lower_limit>
            <ci_upper_limit>0.07</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 4, Treatment Effect</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Pair-wise comparisons</method>
            <param_type>LS means difference</param_type>
            <param_value>-2.88</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.05</ci_lower_limit>
            <ci_upper_limit>3.28</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Estradiol Concentration at Weeks 2 and 4</title>
        <description>The LSMeans refer to overall adjusted mean estradiol concentration.</description>
        <time_frame>2 and 4 weeks from Baseline (Day 0)</time_frame>
        <population>The analysis population consists of all randomized patients who received at least 1 dose of randomized study drug starting at visit 3, who had at least 1 post-dose efficacy assessment. Missing efficacy data were not imputed.</population>
        <group_list>
          <group group_id="O1">
            <title>S-equol 10 mg BID</title>
            <description>20 mg total daily dose of S-equol</description>
          </group>
          <group group_id="O2">
            <title>S-equol 50 mg BID</title>
            <description>100 mg total daily dose of S-equol</description>
          </group>
          <group group_id="O3">
            <title>S-equol 150 mg BID</title>
            <description>300 mg total daily dose of S-equol</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo treatment arm</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Estradiol Concentration at Weeks 2 and 4</title>
          <description>The LSMeans refer to overall adjusted mean estradiol concentration.</description>
          <population>The analysis population consists of all randomized patients who received at least 1 dose of randomized study drug starting at visit 3, who had at least 1 post-dose efficacy assessment. Missing efficacy data were not imputed.</population>
          <units>Estradiol Concentration (pmol/L)</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="41"/>
                <count group_id="O4" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Day 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.0" lower_limit="55.5" upper_limit="102.5"/>
                    <measurement group_id="O2" value="65.7" lower_limit="53.8" upper_limit="77.6"/>
                    <measurement group_id="O3" value="66.1" lower_limit="53.1" upper_limit="79.2"/>
                    <measurement group_id="O4" value="59.6" lower_limit="50.2" upper_limit="69.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="117.3" lower_limit="69.4" upper_limit="165.2"/>
                    <measurement group_id="O2" value="72.2" lower_limit="54.4" upper_limit="90.1"/>
                    <measurement group_id="O3" value="68.1" lower_limit="51.0" upper_limit="85.2"/>
                    <measurement group_id="O4" value="62.1" lower_limit="51.1" upper_limit="73.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.2" lower_limit="-2.4" upper_limit="82.9"/>
                    <measurement group_id="O2" value="6.7" lower_limit="-10.3" upper_limit="23.7"/>
                    <measurement group_id="O3" value="2.0" lower_limit="-9.0" upper_limit="12.9"/>
                    <measurement group_id="O4" value="2.5" lower_limit="-4.5" upper_limit="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2, LSMean</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104.93" lower_limit="81.11" upper_limit="128.76"/>
                    <measurement group_id="O2" value="73.22" lower_limit="49.98" upper_limit="96.46"/>
                    <measurement group_id="O3" value="65.03" lower_limit="41.80" upper_limit="88.26"/>
                    <measurement group_id="O4" value="69.61" lower_limit="46.24" upper_limit="92.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114.0" lower_limit="48.1" upper_limit="179.9"/>
                    <measurement group_id="O2" value="82.8" lower_limit="45.5" upper_limit="120.1"/>
                    <measurement group_id="O3" value="60.0" lower_limit="45.2" upper_limit="74.7"/>
                    <measurement group_id="O4" value="70.4" lower_limit="40.0" upper_limit="100.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.5" lower_limit="-8.4" upper_limit="83.4"/>
                    <measurement group_id="O2" value="20.3" lower_limit="-18.5" upper_limit="59.2"/>
                    <measurement group_id="O3" value="-6.7" lower_limit="-19.1" upper_limit="5.6"/>
                    <measurement group_id="O4" value="10.7" lower_limit="-18.3" upper_limit="39.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4, LSMean</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.89" lower_limit="67.96" upper_limit="133.81"/>
                    <measurement group_id="O2" value="86.56" lower_limit="54.78" upper_limit="118.34"/>
                    <measurement group_id="O3" value="56.03" lower_limit="24.14" upper_limit="87.91"/>
                    <measurement group_id="O4" value="78.77" lower_limit="47.31" upper_limit="110.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0681</p_value>
            <p_value_desc>P-value is adjusted for multiple comparisons and the a priori threshold for statistical significance was P &lt;0.05. Treatment effect averaged across Weeks 2 and 4.</p_value_desc>
            <method>Repeated measures ANCOVA</method>
            <method_desc>Mixed Model: (Estradiol) = Baseline (Estradiol) + Treatment + Site + Weeks + Treatment x Weeks</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 2, Treatment Effect</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Pair-wise comparisons</method>
            <param_type>LS means difference</param_type>
            <param_value>35.32</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.75</ci_lower_limit>
            <ci_upper_limit>68.90</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 2, Treatment Effect</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Pair-wise comparisons</method>
            <param_type>LS means difference</param_type>
            <param_value>3.61</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-29.12</ci_lower_limit>
            <ci_upper_limit>36.34</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 2, Treatment Effect</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Pair-wise comparisons</method>
            <param_type>LS means difference</param_type>
            <param_value>-4.58</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-37.39</ci_lower_limit>
            <ci_upper_limit>28.23</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 4, Treatment Effect</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Pair-wise comparisons</method>
            <param_type>LS means difference</param_type>
            <param_value>22.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-23.56</ci_lower_limit>
            <ci_upper_limit>67.80</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 4, Treatment Effect</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Pair-wise comparisons</method>
            <param_type>LS means difference</param_type>
            <param_value>7.80</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-36.70</ci_lower_limit>
            <ci_upper_limit>52.29</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 4, Treatment Effect</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Pair-wise comparisons</method>
            <param_type>LS means difference</param_type>
            <param_value>-22.74</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-67.44</ci_lower_limit>
            <ci_upper_limit>21.96</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Progesterone Concentration at Week 2 and Week 4</title>
        <description>No repeated measures ANCOVA results are presented for change from Baseline in progesterone concentrations since the model did not converge.</description>
        <time_frame>2 and 4 weeks from Baseline (Day 0)</time_frame>
        <population>The analysis population consists of all randomized patients who received at least 1 dose of randomized study drug starting at visit 3, who had at least 1 post-dose efficacy assessment. Missing efficacy data were not imputed.</population>
        <group_list>
          <group group_id="O1">
            <title>S-equol 10 mg BID</title>
            <description>20 mg total daily dose of S-equol</description>
          </group>
          <group group_id="O2">
            <title>S-equol 50 mg BID</title>
            <description>100 mg total daily dose of S-equol</description>
          </group>
          <group group_id="O3">
            <title>S-equol 150 mg BID</title>
            <description>300 mg total daily dose of S-equol</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo treatment arm</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Progesterone Concentration at Week 2 and Week 4</title>
          <description>No repeated measures ANCOVA results are presented for change from Baseline in progesterone concentrations since the model did not converge.</description>
          <population>The analysis population consists of all randomized patients who received at least 1 dose of randomized study drug starting at visit 3, who had at least 1 post-dose efficacy assessment. Missing efficacy data were not imputed.</population>
          <units>Progesterone Concentration (nmol/L)</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="41"/>
                <count group_id="O4" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Day 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" lower_limit="1.0" upper_limit="1.3"/>
                    <measurement group_id="O2" value="1.1" lower_limit="0.9" upper_limit="1.3"/>
                    <measurement group_id="O3" value="1.3" lower_limit="0.9" upper_limit="1.6"/>
                    <measurement group_id="O4" value="1.1" lower_limit="0.9" upper_limit="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" lower_limit="1.0" upper_limit="1.3"/>
                    <measurement group_id="O2" value="1.3" lower_limit="1.0" upper_limit="1.5"/>
                    <measurement group_id="O3" value="1.1" lower_limit="0.9" upper_limit="1.2"/>
                    <measurement group_id="O4" value="1.0" lower_limit="0.9" upper_limit="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-0.1" upper_limit="0.1"/>
                    <measurement group_id="O2" value="0.1" lower_limit="-0.0" upper_limit="0.3"/>
                    <measurement group_id="O3" value="-0.2" lower_limit="-0.6" upper_limit="0.1"/>
                    <measurement group_id="O4" value="-0.0" lower_limit="-0.1" upper_limit="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0" lower_limit="-4.8" upper_limit="18.9"/>
                    <measurement group_id="O2" value="1.1" lower_limit="0.9" upper_limit="1.2"/>
                    <measurement group_id="O3" value="1.4" lower_limit="0.8" upper_limit="2.0"/>
                    <measurement group_id="O4" value="1.1" lower_limit="0.9" upper_limit="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.9" lower_limit="-5.9" upper_limit="17.8"/>
                    <measurement group_id="O2" value="-0.0" lower_limit="-0.1" upper_limit="0.0"/>
                    <measurement group_id="O3" value="0.1" lower_limit="-0.2" upper_limit="0.4"/>
                    <measurement group_id="O4" value="-0.0" lower_limit="-0.1" upper_limit="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in the Menopause Rating Scale Total Score From Baseline at Week 4</title>
        <description>MRS consists of 11 menopause symptoms. The scoring scheme is simple, i.e., the score increases point by point with increasing severity of subjectively perceived symptoms in each of the 11 items (severity 0 [no complaints] 4 scoring points [extremely severe symptoms]). The respondent provides her personal perception by checking one of 5 possible boxes of &quot;severity&quot; for each of the items. The composite score (total score) is the sum of the 11 item scores, which can range from 0 (no symptoms) to 44 (extremely severe symptoms). Low total scores represent less severe menopause symptoms while higher scores represent more severe symptoms.</description>
        <time_frame>4 weeks from Baseline (Day 0)</time_frame>
        <population>The analysis population consists of all randomized patients who received at least 1 dose of randomized study drug starting at visit 3, who had at least 1 post-dose efficacy assessment. Missing efficacy data were not imputed.</population>
        <group_list>
          <group group_id="O1">
            <title>S-equol 10 mg BID</title>
            <description>20 mg total daily dose of S-equol</description>
          </group>
          <group group_id="O2">
            <title>S-equol 50 mg BID</title>
            <description>100 mg total daily dose of S-equol</description>
          </group>
          <group group_id="O3">
            <title>S-equol 150 mg BID</title>
            <description>300 mg total daily dose of S-equol</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo treatment arm</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in the Menopause Rating Scale Total Score From Baseline at Week 4</title>
          <description>MRS consists of 11 menopause symptoms. The scoring scheme is simple, i.e., the score increases point by point with increasing severity of subjectively perceived symptoms in each of the 11 items (severity 0 [no complaints] 4 scoring points [extremely severe symptoms]). The respondent provides her personal perception by checking one of 5 possible boxes of &quot;severity&quot; for each of the items. The composite score (total score) is the sum of the 11 item scores, which can range from 0 (no symptoms) to 44 (extremely severe symptoms). Low total scores represent less severe menopause symptoms while higher scores represent more severe symptoms.</description>
          <population>The analysis population consists of all randomized patients who received at least 1 dose of randomized study drug starting at visit 3, who had at least 1 post-dose efficacy assessment. Missing efficacy data were not imputed.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="41"/>
                <count group_id="O4" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Day 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.9" lower_limit="14.3" upper_limit="19.5"/>
                    <measurement group_id="O2" value="17.3" lower_limit="14.6" upper_limit="20.1"/>
                    <measurement group_id="O3" value="15.7" lower_limit="13.3" upper_limit="18.1"/>
                    <measurement group_id="O4" value="14.5" lower_limit="12.6" upper_limit="16.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.5" lower_limit="8.7" upper_limit="14.2"/>
                    <measurement group_id="O2" value="10.8" lower_limit="8.5" upper_limit="13.1"/>
                    <measurement group_id="O3" value="9.7" lower_limit="7.7" upper_limit="11.7"/>
                    <measurement group_id="O4" value="9.9" lower_limit="8.3" upper_limit="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.3" lower_limit="-7.0" upper_limit="3.7"/>
                    <measurement group_id="O2" value="-6.4" lower_limit="-8.3" upper_limit="4.4"/>
                    <measurement group_id="O3" value="-6.0" lower_limit="-8.5" upper_limit="3.6"/>
                    <measurement group_id="O4" value="-4.6" lower_limit="-6.4" upper_limit="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Change From Baseline in Menopause Rating Scale (MRS) - Sum of 3 Symptoms (Irritability, Dry Vagina, Joint/Muscular Discomfort)</title>
        <description>Note: Each MRS symptoms is assigned a score from 0 to 4 (0 = 'None' and 4 = 'Extremely severe').
Scores for Symptoms 5, 10, and 11 on the MRS were summed and analyzed. Total summed scores ranged from 0 to 12, with higher scores representing more severe symptoms.</description>
        <time_frame>4 weeks from Baseline (Day 0)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>S-equol 10 mg BID</title>
            <description>20 mg total daily dose of S-equol</description>
          </group>
          <group group_id="O2">
            <title>S-equol 50 mg BID</title>
            <description>100 mg total daily dose of S-equol</description>
          </group>
          <group group_id="O3">
            <title>S-equol 150 mg BID</title>
            <description>300 mg total daily dose of S-equol</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo treatment arm</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Menopause Rating Scale (MRS) - Sum of 3 Symptoms (Irritability, Dry Vagina, Joint/Muscular Discomfort)</title>
          <description>Note: Each MRS symptoms is assigned a score from 0 to 4 (0 = 'None' and 4 = 'Extremely severe').
Scores for Symptoms 5, 10, and 11 on the MRS were summed and analyzed. Total summed scores ranged from 0 to 12, with higher scores representing more severe symptoms.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="41"/>
                <count group_id="O4" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Day 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" lower_limit="3.2" upper_limit="4.9"/>
                    <measurement group_id="O2" value="4.2" lower_limit="3.3" upper_limit="5.2"/>
                    <measurement group_id="O3" value="4.0" lower_limit="3.2" upper_limit="4.8"/>
                    <measurement group_id="O4" value="3.4" lower_limit="2.8" upper_limit="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" lower_limit="2.0" upper_limit="3.7"/>
                    <measurement group_id="O2" value="2.8" lower_limit="2.1" upper_limit="3.6"/>
                    <measurement group_id="O3" value="2.5" lower_limit="1.9" upper_limit="3.2"/>
                    <measurement group_id="O4" value="2.9" lower_limit="2.3" upper_limit="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.3" lower_limit="-1.9" upper_limit="-0.7"/>
                    <measurement group_id="O2" value="-1.5" lower_limit="-2.3" upper_limit="-0.8"/>
                    <measurement group_id="O3" value="-1.5" lower_limit="-2.2" upper_limit="-0.7"/>
                    <measurement group_id="O4" value="-0.5" lower_limit="-1.1" upper_limit="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Percentage Change From Baseline in Menopause Rating Scale (MRS) - Sum of 3 Symptoms (Irritability, Dry Vagina, Joint/Muscular Discomfort)</title>
        <description>Percentage change from Baseline at Week 4 = (Week 4 value - Day 0 value)/(Day 0 value) x 100. Note: Each MRS symptoms is assigned a score from 0 to 4 (0 = 'None' and 4 = 'Extremely severe').</description>
        <time_frame>4 weeks from Baseline (Day 0)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>S-equol 10 mg BID</title>
            <description>20 mg total daily dose of S-equol</description>
          </group>
          <group group_id="O2">
            <title>S-equol 50 mg BID</title>
            <description>100 mg total daily dose of S-equol</description>
          </group>
          <group group_id="O3">
            <title>S-equol 150 mg BID</title>
            <description>300 mg total daily dose of S-equol</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo treatment arm</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change From Baseline in Menopause Rating Scale (MRS) - Sum of 3 Symptoms (Irritability, Dry Vagina, Joint/Muscular Discomfort)</title>
          <description>Percentage change from Baseline at Week 4 = (Week 4 value - Day 0 value)/(Day 0 value) x 100. Note: Each MRS symptoms is assigned a score from 0 to 4 (0 = 'None' and 4 = 'Extremely severe').</description>
          <units>Percentage Change</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="41"/>
                <count group_id="O4" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.1" lower_limit="-49.5" upper_limit="-8.7"/>
                    <measurement group_id="O2" value="-32.7" lower_limit="-50.6" upper_limit="-14.8"/>
                    <measurement group_id="O3" value="-30.2" lower_limit="-49.6" upper_limit="-10.9"/>
                    <measurement group_id="O4" value="-0.6" lower_limit="-23.2" upper_limit="21.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0475</p_value>
            <p_value_desc>P-value was not adjusted for multiple comparisons and the a priori threshold for statistical significance was P &lt;0.05.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>Wilcoxon Mann-Whitney test: S-equol treatment group versus Placebo: Percentage Change from Baseline at Week 4</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0258</p_value>
            <p_value_desc>P-value was not adjusted for multiple comparisons and the a priori threshold for statistical significance P &lt;0.05.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>Wilcoxon Mann-Whitney test: S-equol treatment group versus Placebo: Percentage Change from Baseline at Week 4</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0281</p_value>
            <p_value_desc>P-value was not adjusted for multiple comparisons and the a priori threshold for statistical significance was P &lt;0.05.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>Wilcoxon Mann-Whitney test: S-equol treatment group versus Placebo: Percentage Change from Baseline at Week 4</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>All three S-equol treatment arms were aggregated and compared to placebo.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0645</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Change From Baseline in Menopause Rating Scale (MRS) - Sum of 3 Symptoms (Irritability, Dry Vagina, Joint/Muscular Discomfort) - S-equol Groups Combined</title>
        <description>The following analysis shows the results when the S-equol groups (S-equol 20 mg total daily dose, 100 mg total daily dose, and 300 mg total daily dose) are combined and regarded as a single treatment group.
Note: Each MRS symptoms was assigned a score from 0 to 4 (0 = 'None' and 4 = 'Extremely severe'</description>
        <time_frame>4 weeks from Baseline (Day 0)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>S-equol Groups Combined</title>
            <description>The S-equol groups (S-equol 20 mg total daily dose, 100 mg total daily dose, and 300 mg total daily dose) were combined and regarded as a single treatment group.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo treatment arm</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Menopause Rating Scale (MRS) - Sum of 3 Symptoms (Irritability, Dry Vagina, Joint/Muscular Discomfort) - S-equol Groups Combined</title>
          <description>The following analysis shows the results when the S-equol groups (S-equol 20 mg total daily dose, 100 mg total daily dose, and 300 mg total daily dose) are combined and regarded as a single treatment group.
Note: Each MRS symptoms was assigned a score from 0 to 4 (0 = 'None' and 4 = 'Extremely severe'</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Day 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" lower_limit="3.6" upper_limit="4.6"/>
                    <measurement group_id="O2" value="3.4" lower_limit="2.8" upper_limit="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" lower_limit="2.3" upper_limit="3.2"/>
                    <measurement group_id="O2" value="2.9" lower_limit="2.3" upper_limit="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.4" lower_limit="-1.8" upper_limit="-1.0"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-1.1" upper_limit="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0097</p_value>
            <p_value_desc>P-value is adjusted for multiple comparisons and the a priori threshold for statistical significance was P &lt;0.05.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>Wilcoxon Mann-Whitney test: S-equol groups combined versus Placebo: Change from Baseline at Week 4</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Precentage Change in the Menopause Rating Scale Total Score From Baseline at Week 4</title>
        <description>Percentage change from Baseline at Week 4 = (Week 4 value - Day 0 value)/(Day 0 value) x 100. Note: MRS consists of 11 symptoms, where each symptom is assigned a score from 0 to 4 (0 = 'None' and 4 = 'Extremely severe').</description>
        <time_frame>4 weeks from Baseline (Day 0)</time_frame>
        <population>The analysis population consists of all randomized patients who received at least 1 dose of randomized study drug starting at visit 3, who had at least 1 post-dose efficacy assessment. Missing efficacy data were not imputed.</population>
        <group_list>
          <group group_id="O1">
            <title>S-equol 10 mg BID</title>
            <description>20 mg total daily dose of S-equol</description>
          </group>
          <group group_id="O2">
            <title>S-equol 50 mg BID</title>
            <description>100 mg total daily dose of S-equol</description>
          </group>
          <group group_id="O3">
            <title>S-equol 150 mg BID</title>
            <description>300 mg total daily dose of S-equol</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo treatment arm</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Precentage Change in the Menopause Rating Scale Total Score From Baseline at Week 4</title>
          <description>Percentage change from Baseline at Week 4 = (Week 4 value - Day 0 value)/(Day 0 value) x 100. Note: MRS consists of 11 symptoms, where each symptom is assigned a score from 0 to 4 (0 = 'None' and 4 = 'Extremely severe').</description>
          <population>The analysis population consists of all randomized patients who received at least 1 dose of randomized study drug starting at visit 3, who had at least 1 post-dose efficacy assessment. Missing efficacy data were not imputed.</population>
          <units>Percentage Change</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="41"/>
                <count group_id="O4" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-36.7" lower_limit="-46.8" upper_limit="-26.6"/>
                    <measurement group_id="O2" value="-37.4" lower_limit="-46.9" upper_limit="-27.9"/>
                    <measurement group_id="O3" value="-30.6" lower_limit="-43.8" upper_limit="-17.4"/>
                    <measurement group_id="O4" value="-27.4" lower_limit="-39.2" upper_limit="15.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4352</p_value>
            <p_value_desc>P-value was not adjusted for multiple comparisons and the a priori threshold for statistical significance was P &lt;0.05.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>Wilcoxon Mann-Whitney test: S-equol treatment group versus Placebo: Percentage Change from Baseline at Week 4</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2600</p_value>
            <p_value_desc>P-value was not adjusted for multiple comparisons and the a priori threshold for statistical significance was P &lt;0.05.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>Wilcoxon Mann-Whitney test: S-equol treatment group versus Placebo: Percentage Change from Baseline at Week 4</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7037</p_value>
            <p_value_desc>P-value was not adjusted for multiple comparisons and the a priori threshold for statistical significance was P &lt;0.05.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>Wilcoxon Mann-Whitney test: S-equol treatment group versus Placebo: Percentage Change from Baseline at Week 4</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>All three S-equol treatment arms were aggregated and compared to placebo.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7155</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Change From Baseline in Menopause Rating Scale (MRS) - Dryness of Vagina- S-equol Groups Combined</title>
        <description>The following analysis pre-specified the combining of all S-equol groups (S-equol 20 mg total daily dose, 100 mg total daily dose, and 300 mg total daily dose) into a single treatment group. The results from the Wilcoxon-Mann-Whitney test (pair-wise test), based on the change from Baseline at Week 4, are presented.
Note: Dryness of Vagina was assigned a score from 0 to 4 (0 = 'None' and 4 = 'Extremely severe'</description>
        <time_frame>4 weeks from Baseline (Day 0)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>S-equol Groups Combined</title>
            <description>The S-equol groups (S-equol 20 mg total daily dose, 100 mg total daily dose, and 300 mg total daily dose) were combined and regarded as a single treatment group.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo treatment arm</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Menopause Rating Scale (MRS) - Dryness of Vagina- S-equol Groups Combined</title>
          <description>The following analysis pre-specified the combining of all S-equol groups (S-equol 20 mg total daily dose, 100 mg total daily dose, and 300 mg total daily dose) into a single treatment group. The results from the Wilcoxon-Mann-Whitney test (pair-wise test), based on the change from Baseline at Week 4, are presented.
Note: Dryness of Vagina was assigned a score from 0 to 4 (0 = 'None' and 4 = 'Extremely severe'</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Day 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" lower_limit="1.2" upper_limit="1.7"/>
                    <measurement group_id="O2" value="1.5" lower_limit="1.1" upper_limit="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" lower_limit="0.8" upper_limit="1.3"/>
                    <measurement group_id="O2" value="1.4" lower_limit="1.0" upper_limit="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" lower_limit="-0.6" upper_limit="-0.3"/>
                    <measurement group_id="O2" value="-0.1" lower_limit="-0.4" upper_limit="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0381</p_value>
            <p_value_desc>P-value is adjusted for multiple comparisons and the a priori threshold for statistical significance was P &lt;0.05.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>Wilcoxon Mann-Whitney test: S-equol groups combined versus Placebo: Change from Baseline at Week 4</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from the time of signing of the informed consent document through the follow-up visit or early termination visit (whichever occurred first).</time_frame>
      <desc>An adverse event was followed to a satisfactory resolution, until it became stable, or until it could be explained by another known cause(s) and clinical judgment indicated that further evaluation was not warranted, or 30 days from the date of last study drug dose for adverse events not related to study drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>S-equol 10 mg BID</title>
          <description>20 mg total daily dose of S-equol</description>
        </group>
        <group group_id="E2">
          <title>S-equol 50 mg BID</title>
          <description>100 mg total daily dose of S-equol</description>
        </group>
        <group group_id="E3">
          <title>S-equol 150 mg BID</title>
          <description>300 mg total daily dose of S-equol</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>Placebo treatment arm</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (13.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle Fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Pulmonary Embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (13.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Cardiac Disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Abdominal Distension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Abnormal Feces</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Hemorrhoids</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="43"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Injection Site Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Immune System Disorders</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Seasonal Allergy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Fungal Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Gingival Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Lower Respiratory Tract Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Nail Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Oral Herpes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="42"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Vaginal Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropod Bite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Joint Sprain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Mouth Injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Muscle Strain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Procedural Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine Aminotransferase Increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Blood Glucose Increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Blood Lactate Dehydrogenase Increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Blood Triglycerides Increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Estradiol Increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Smear Cervix Abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Mood Swings</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Glycosuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast Tenderness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Cervical Dysplasia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Endometrial Hypertrophy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Vaginal Discharge</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Vaginal Hemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Vulvovaginal Erythema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dry Throat</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Oropharyngeal Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Actinic Keratosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Dermatitis Contact</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Rash Macular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Rash Pruritic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Skin Hypertrophy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot Flush</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Per-protocol, an ANOVA model was to be used for the primary efficacy analysis. However using statistical adjustment of baseline values, ANCOVA could be more a more powerful analysis (Vickers AJ. BMC Med Res Methodology. 2001;1:6. Epub 2001 Jun 28).</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Rick Schwen, PhD, DABT, RAC / Vice President of Regulatory Affairs</name_or_title>
      <organization>Ausio Pharmaceuticals, LLC</organization>
      <phone>513-731-0222</phone>
      <email>rick@ausiopharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

